Trial Profile
Efficacy and safety comparison of insulin detemir plus insulin aspart versus insulin glargine plus insulin aspart in type 2 diabetes.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Feb 2017
Price :
$35
*
At a glance
- Drugs Insulin detemir (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms NOVEL-2
- Sponsors Novo Nordisk
- 07 Jul 2009 Actual patient number changed from 319 to 324 as reported by ClinicalTrials.gov.
- 07 Jul 2009 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
- 27 Sep 2006 Status change